NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) News Today $2.60 -0.20 (-7.14%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$2.57▼$2.8750-Day Range$0.65▼$3.3752-Week Range$0.61▼$3.70Volume785,100 shsAverage Volume514,193 shsMarket Capitalization$121.08 millionP/E RatioN/ADividend YieldN/APrice Target$3.17 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Media Mentions By Week CRVS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVS News Sentiment▼0.300.78▲Average Medical News Sentiment CRVS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVS Articles This Week▼31▲CRVS Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIs Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?finance.yahoo.com - May 26 at 1:52 PMCorvus Pharmaceuticals (NASDAQ:CRVS) Research Coverage Started at StockNews.comamericanbankingnews.com - May 21 at 7:57 AMCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Director Buys $24,500.00 in Stockamericanbankingnews.com - May 18 at 8:14 AMCorvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphomafinance.yahoo.com - May 17 at 9:19 AMCorvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma Marketseekingalpha.com - May 12 at 6:35 PMCorvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Whyfinance.yahoo.com - May 12 at 1:35 PMCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Resultsfinanznachrichten.de - May 10 at 8:04 PMWhy Are Corvus Pharmaceuticals Trading Higher Todaybenzinga.com - May 10 at 3:02 PMCantor Fitzgerald Maintains Corvus Pharmaceuticals (CRVS) Overweight Recommendationmsn.com - May 9 at 7:23 PMCorvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $4.00 at Cantor Fitzgeraldamericanbankingnews.com - May 9 at 7:52 AMCorvus Pharmaceuticals (NASDAQ:CRVS) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - May 9 at 4:36 AMCorvus Pharmaceuticals (CRVS) Set to Announce Earnings on Mondayamericanbankingnews.com - May 7 at 3:48 AMCorvus Pharmaceuticals (NASDAQ:CRVS) Now Covered by StockNews.comamericanbankingnews.com - April 29 at 4:26 AMCorvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated at StockNews.comamericanbankingnews.com - April 21 at 5:22 AMCorvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023finance.yahoo.com - April 20 at 1:43 PMCorvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meetingfinance.yahoo.com - April 17 at 9:28 AMStockNews.com Initiates Coverage on Corvus Pharmaceuticals (NASDAQ:CRVS)americanbankingnews.com - April 13 at 2:46 AMCantor Fitzgerald Brokers Boost Earnings Estimates for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)americanbankingnews.com - April 5 at 2:50 AMCorvus Pharmaceuticals cut its CEO's base salary by $265,000. Here's the catch.bizjournals.com - April 4 at 10:13 PMCorvus Pharmaceuticals (NASDAQ:CRVS) Coverage Initiated by Analysts at StockNews.comamericanbankingnews.com - April 4 at 4:28 AMCPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphomafinance.yahoo.com - April 3 at 10:26 AMCorvus Pharmaceuticals (NASDAQ:CRVS) Receives Neutral Rating from Mizuhoamericanbankingnews.com - April 3 at 3:52 AMCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - March 30 at 8:54 AMCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Resultsfinanznachrichten.de - March 29 at 5:35 PMCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Resultsfinance.yahoo.com - March 28 at 4:21 PMCorvus Pharmaceuticals Earnings Previewmsn.com - March 27 at 1:01 PMCorvus Pharmaceuticals (NASDAQ:CRVS) Now Covered by Analysts at StockNews.comamericanbankingnews.com - March 27 at 4:30 AMCorvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023finance.yahoo.com - March 21 at 7:51 PMCorvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meetingfinance.yahoo.com - March 14 at 6:00 PMCorvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-Emergencefinance.yahoo.com - February 21 at 3:39 PMCorvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversalfinance.yahoo.com - February 21 at 10:38 AM'Block-and-lock' HIV path targeted by UCSF professor, Peninsula drug companyfinance.yahoo.com - February 21 at 10:38 AMQuite a few insiders invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) last year which is positive news for shareholdersfinance.yahoo.com - February 2 at 9:25 AMCorvus Pharmaceuticalsforbes.com - January 20 at 10:37 PMCRVS.A - | Stock Price & Latest News | Reutersreuters.com - January 13 at 1:56 PMCorvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Expositionfinance.yahoo.com - December 12 at 3:34 PMCorvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022finance.yahoo.com - December 5 at 6:06 PMJames Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatologyfinance.yahoo.com - November 14 at 10:47 AMCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Resultsapnews.com - November 4 at 10:03 AMCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Resultsfinanznachrichten.de - November 4 at 5:01 AMCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Resultsfinance.yahoo.com - November 4 at 5:01 AMCorvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Expositionfinance.yahoo.com - November 3 at 11:58 AMEarnings Preview For Corvus Pharmaceuticalsmsn.com - November 2 at 3:54 PMCorvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022finance.yahoo.com - October 27 at 5:42 PMCorvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancerfinance.yahoo.com - October 25 at 6:27 PMCorvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck Cancerfinance.yahoo.com - September 27 at 2:16 PMCorvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in Chinafinance.yahoo.com - September 26 at 6:04 PMA number of insiders bought Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) stock last year, which is great news for shareholdersnasdaq.com - September 15 at 7:41 AMCorvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 5:50 PMGreat news for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS): Insiders acquired stock in large numbers last yearfinance.yahoo.com - August 26 at 7:06 AM Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Larimar Therapeutics News Puma Biotechnology News Organigram News Heron Therapeutics News Esperion Therapeutics News ProPhase Labs News DURECT News LumiraDx News Mereo BioPharma Group News ProQR Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:CRVS) was last updated on 5/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.